Peptides for menopause symptoms: what the science actually supports

What did @janicebelanern actually say?

The creator recommended three peptides for women in menopause: BPC-157 combined with TB-500 (calling it the "Wolverine Stack") for gut health, inflammation, and joint pain; PT-141 as a sublingual troche for libido; and GLP-1 (she said "GOP one," clearly meaning semaglutide or a similar GLP-1 receptor agonist) for lowering A1C, reducing inflammation, and weight loss. She framed all three as personal experience and invited followers to DM her for details. That last part is where things get complicated from a regulatory standpoint, but let's address the science first.

The claims are a mix of things that have legitimate clinical footing, things that are plausible but overstated, and at least one claim that warrants real scrutiny. She is not operating in the realm of fiction, but she is also not operating in the realm of a clinical summary.

Does the science back this up?

Partially, and it depends heavily on which peptide you are talking about. The evidence base is not equal across these three. PT-141 (bremelanotide) has the strongest regulatory standing of the group. BPC-157 and TB-500 have mostly preclinical data. GLP-1 agonists are well-studied, but calling them "peptides" in the same breath as BPC-157 blurs an important line.

PT-141 is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women, though its use in menopausal women is off-label. A randomized controlled trial by Clayton et al. (2016, Journal of Sexual Medicine) showed statistically significant improvements in sexual desire. The sublingual troche delivery she describes is a compounded formulation, not the approved injectable, which matters clinically. BPC-157 has shown anti-inflammatory and tissue-healing effects in rodent models (Sikiric et al., 2018, Current Pharmaceutical Design), but human RCT data remains essentially absent. TB-500's human data is similarly sparse. GLP-1 receptor agonists like semaglutide have robust trial data, including SUSTAIN and STEP trials, confirming A1C reduction and weight loss in humans.

What did they get wrong (or right)?

She got PT-141 mostly right. It is a real compound with real evidence and real FDA approval for a closely related indication. Describing it as something that helps "get that spark back" is a reasonable lay description of its mechanism, which involves melanocortin receptors rather than hormones directly.

She got GLP-1 mostly right in terms of outcomes, A1C reduction and weight loss are well-documented, but framing it casually as a peptide stack item alongside BPC-157 obscures that GLP-1 agonists are prescription medications with significant side effect profiles, including nausea, pancreatitis risk, and thyroid concerns flagged in FDA labeling.

The "Wolverine Stack" claim is where the evidence gets thin fast. Calling BPC-157 plus TB-500 a solution for joint pain and gut health in menopausal women specifically is a stretch. There are no human trials in menopausal populations. The animal data is interesting, not conclusive. Presenting it with the same confidence as GLP-1 outcomes is misleading by equivalence.

• PT-141 sublingual troche: compounded, not FDA-approved in that form. The approved version is injectable.
• BPC-157 and TB-500: no human RCTs. Rodent data only as of mid-2024.
• GLP-1 claim on A1C: accurate but requires medical supervision and carries real risks she did not mention.

What should you actually know?

If you are a woman in menopause researching peptides after watching this video, here is what a clinician would want you to understand before you DM anyone on TikTok.

First, "peptide" is a broad term that gets used to bundle FDA-approved drugs, compounded medications, and research chemicals into one lifestyle category. They are not equivalent in safety profile, evidence base, or legal status. GLP-1 agonists are prescription drugs with monitoring requirements. PT-141 in troche form is a compounded preparation, meaning it is not FDA-approved in that delivery format even though the active ingredient has approval elsewhere. BPC-157 and TB-500 are not FDA-approved for any indication and are sold in the US primarily as research chemicals.

Second, menopausal joint pain, low energy, and libido changes are real, under-treated, and worth addressing. The peptide category may eventually yield useful interventions. But "eventually" is doing a lot of work in that sentence. Right now, for menopausal symptoms, there is better evidence for hormone therapy, FDA-approved HSDD treatments, and lifestyle interventions than for most of the peptides named here.

Third, any creator inviting you to DM them for peptide details is operating in a space that warrants caution. Telehealth platforms with licensed providers and transparent prescribing protocols exist for a reason.